Cargando…

Greater uptake, an alternative reimbursement methodology needed to realize cost-saving potential of oncology biosimilars in the United States

BACKGROUND: Biologics are an important treatment option for solid tumors and hematological malignancies but are a primary driver of health care spending growth. The United States has yet to realize the promise of reduced costs via biosimilars because of slow uptake, partially resulting from commerci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Jingyan, Carioto, Jennifer, Pyenson, Bruce, Smith, Rebecca, Jacobson, Nathaniel, Pittinger, Sean, Shelbaya, Ahmed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394213/ https://www.ncbi.nlm.nih.gov/pubmed/34677089 http://dx.doi.org/10.18553/jmcp.2021.21202

Ejemplares similares

Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and Physicians
por: Yang, Jingyan, et al.
Publicado: (2021)

Barriers to Oncology Biosimilars Uptake in the United States
por: Nabhan, Chadi, et al.
Publicado: (2018)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
por: Kawalec, Paweł, et al.
Publicado: (2017)

Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives
por: Yang, Jingyan, et al.
Publicado: (2021)

Economic evaluation of biosimilars for reimbursement purposes – what, when, how?
por: Moorkens, Evelien, et al.
Publicado: (2020)

Biosimilars in oncology
por: Tabernero, Josep
Publicado: (2018)

Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?
por: Kim, Yujeong, et al.
Publicado: (2020)

Potential Cost-Savings From the Use of the Biosimilars in Slovakia
por: Tesar, Tomas, et al.
Publicado: (2020)

Pricing and reimbursement of novel oncology drugs in Sweden
por: Haglund, Mattias, et al.
Publicado: (2014)

Biosimilars: How Can Payers Get Long-Term Savings?
por: Mestre-Ferrandiz, Jorge, et al.
Publicado: (2016)

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019)

Ocular Oncology: Saving Sight, Saving Lives
por: Gündüz, Ahmet Kaan
Publicado: (2018)

Clinical considerations for the development of biosimilars in oncology
por: Socinski, Mark A, et al.
Publicado: (2015)

Preparing for the incoming wave of biosimilars in oncology
por: Wolff-Holz, Elena, et al.
Publicado: (2018)

Policies for biosimilar uptake in Europe: An overview
por: Moorkens, Evelien, et al.
Publicado: (2017)

Trends in Reimbursement for Index Surgical Oncology Procedures in Contemporary Practice: Declining Reimbursement for Surgical Oncology Procedures—How Low Do We Go?
por: Hydrick, Thomas C., et al.
Publicado: (2022)

Realizing and Allocating Savings From Improving Health Care Quality and Efficiency
por: Fox, Daniel M
Publicado: (2010)

Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis
por: Patel, Dipen, et al.
Publicado: (2019)

Development of biosimilars in an era of oncologic drug shortages
por: Li, Edward, et al.
Publicado: (2015)

Regulatory considerations in oncologic biosimilar drug development
por: Macdonald, Judith C, et al.
Publicado: (2015)

Correction: Preparing for the incoming wave of biosimilars in oncology
Publicado: (2018)

The role of biosimilars in value-based oncology care
por: Patel, Kashyap B, et al.
Publicado: (2018)

Current and future roles of biosimilars in oncology practice
por: Konstantinidou, Sofia, et al.
Publicado: (2020)

Biosimilars in Oncology: Latest Trends and Regulatory Status
por: Joshi, Deeksha, et al.
Publicado: (2022)

Oncology biosimilars: New developments and future directions
por: Bachu, Rinda Devi, et al.
Publicado: (2022)

Reimbursement versus effort in medical physics practice in radiation oncology
por: Herman, Michael G., et al.
Publicado: (2003)

Biosimilar Uptake: The Importance of Healthcare Provider Education
por: Oskouei, Sonia Tadjalli, et al.
Publicado: (2021)

Biosimilar medicines uptake: The role of the clinical pharmacist
por: Okoro, Roland Nnaemeka
Publicado: (2021)

Assessment of Methodological Quality of Economic Evaluations in Belgian Drug Reimbursement Applications
por: Simoens, Steven
Publicado: (2013)

Uptake of biosimilar trastuzumab in Denmark compared with other European countries: a comparative study and discussion of factors influencing implementation and uptake of biosimilars
por: Azuz, Samuel, et al.
Publicado: (2021)

Presently available biosimilars in hematology-oncology: G-CSF
por: Gascon, Pere
Publicado: (2012)

Biosimilar agents in oncology/haematology: from approval to practice
por: Niederwieser, Dietger, et al.
Publicado: (2011)

Biosimilars in the United States: Considerations for Oncology Advanced Practitioners
por: Mayden, Kelley D., et al.
Publicado: (2015)

Integrating Biosimilars Into Oncology Practice: Implications for the Advanced Practitioner
por: Campen, Christopher J.
Publicado: (2017)

Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
por: Francescon, Sara, et al.
Publicado: (2016)

Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology
por: Giuliani, Rosa, et al.
Publicado: (2019)

Physicians’ perceptions of the uptake of biosimilars: a systematic review
por: Sarnola, Kati, et al.
Publicado: (2020)

Comparison of Uptake and Prices of Biosimilars in the US, Germany, and Switzerland
por: Carl, David L., et al.
Publicado: (2022)

Demonstrations and Designs of Alternative Reimbursement Methods for Home Health Services
Publicado: (1989)

The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC)
por: Fernandes, G.S., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d6vnfc7cca3b0jabgro0kk1tnb